Nasal Polyps Case Studies
Cases in Practice: Applying Proposed Care Pathways for Interdisciplinary Collaboration to the Management of Nasal Polyps
Speakers: Stacey Denham, MSW, MPH, Public Health ManagerStella Lee, MD, Director of the Brigham Sinus Center
Duration: 60 minutes
Presented on: November 2, 2023
Stacey Denham, MSW, MPH
Stacey Denham, MSW, MPH
Public Health ManagerStacey Denham, MSW, MPH, is a Public Health Manager at the Asthma and Allergy Foundation of America (AAFA), the nation’s oldest and leading asthma and allergy charity. She holds an MSW and MPH from Tulane University with a concentration in Maternal and Child Health. Stacey has worked in the asthma and allergy field for over 15 years with an emphasis in community health. She has worked both locally in her community of New Orleans and internationally with non-profit organizations. Stacy believes in the power, diversity, and resilience of each community and the leaders that reside in them to bring healthy behavior change to positive health outcomes. Currently, Stacey resides in New Orleans with her family, where they can be found bike riding, trying out new food spots, and going to festivals.
Stella Lee, MD
Stella Lee, MD
Director of the Brigham Sinus CenterStella Lee, MD is a fellowship-trained rhinologist and chief of rhinology at Brigham and Women’s Hospital (BWH)/Harvard Medical School in Boston, Massachusetts. She is a clinician scientist developing novel management strategies for the care of patients with inflammatory upper airway disease and is a leader in developing therapeutics for airway inflammation. Before joining BWH, Dr. Lee was the division chief for sino-nasal disorders and allergy in the Department of Otolaryngology at the University of Pittsburgh Medical Center for ten years. Her research interests include defining inflammatory endotypes of chronic rhinosinusitis, the impact of environmental pollution on airway inflammation, and the development of basic to translational approaches to solve chronic inflammation.
Cases in Practice: Applying Proposed Care Pathways for Interdisciplinary Collaboration to the Management of Nasal PolypsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Asthma and Allergy Foundation of America (AAFA)
ACKNOWLEDGEMENTThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
DATE OF RELEASE/EXPIRATIONNovember 2nd, 2023. Expires November 2nd, 2024.
TARGET AUDIENCEThe intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and physician assistants, and other clinicians involved in the management of patients with nasal polyps (NPs).
STATEMENT OF NEED/PROGRAM OVERVIEWClinicians on the frontlines of care for chronic rhinosinusitis with nasal polyps – including ear, nose, and throat specialists (ENTs) and allergists-- are largely unaware of the underlying pathophysiology driven by type 2 (T2) inflammation that leads to NPs and drives recurrent disease and treatment resistance. Yet understanding these mechanisms may be key to selecting appropriate treatment. Further, as the management of NPs has evolved, several organizations and professional societies, including professional rhinology organizations, have developed guidelines or consensus statements positioning the role of biologic agents in NP care.
Join a panel that includes an ear, nose, and throat specialist (ENT) and a representative from AAFA to discuss cases illustrating the adoption of biologics as a therapeutic option for NPs and the importance of multidisciplinary care. Panelists will review the underlying pathophysiology of NPs driven by type 2 (T2) inflammation that leads to NPs and drives recurrent disease and treatment resistance. The experts will also explore the place of biologics in NP care and share strategies to encourage collaboration among ENTs, allergists, and patients.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Demonstrate ability to apply guidelines and expert recommendations to the management of severe, resistant NPs based on patient factors, including comorbidities, response to past treatments, and risk of recurrence
- Discuss strategies for implementing interdisciplinary collaborative care between ENTs, allergists, and other members of the care team managing patients with NPs and T2‐driven comorbidities
- Describe the shared inflammatory pathophysiology of NPs and common comorbidities
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPSGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Stella Lee, MD
Section Chief - Rhinology
Brigham and Women’s Hospital
Harvard Medical School
Consulting Fee (e.g., Advisory Board): AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron
Stacey Denham, MSW, MPH
Public Health Manager
Asthma and Allergy Foundation of America (AAFA)
Nothing to disclose
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
Technical Support:For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.